Table 5. Combined summary data for clinical trials with DPP-4 inhibitor sitagliptin only and in combination with other anti-diabetic drugs.

^LegendMET: metformin. FPG: fasting plasma glucose. BID: twice daily. QD: once daily. NR: not reported. ¹ From baseline. ² Fraction of patients (in %) with HbA1c ≤ 7% at the end of the study. ³ Fraction of patients with adverse effects (in %). ⁴ MET < 1500 mg/d. ⁵ MET titrated to 1500 mg/d. ⁶ Glipizide titrated to 20 mg/d. ^a Placebo-subtracted mean change. ^b Least squares mean change.